Boston Scientific Corporation (BSX), a prominent name in the biotech market, consistently attracts attention and investments. Its performance is steadily driving it towards an all-time high, promising favorable returns for long-term investors. Analysts are confident in Boston Scientific's ability to break out again. Jefferies and TD Cowen have reiterated Buy Ratings on Boston Scientific, with price targets of $130 and $115 respectively. Moreover, FLPUTNAM INVESTMENT MANAGEMENT CO has recently added 95,234 BSX shares to their portfolio. The corporation's Q2 2025 results are deemed bullish. BSX's performance has outpaced the general Healthcare sector and it has been recognized for its low volatility. However, insider transactions have raised concerns, despite the bullish market sentiment. Boston Scientific continues to innovate, securing FDA Labeling Expansion for its FARAPULSE Pulsed Field Ablation (PFA) System. The company's Chief Financial Officer (CFO) Dan Brennan is set to retire, with Jon Monson succeeding him. Boston Scientific recently concluded a €1.5 billion offering of senior notes and profited from a 117% growth in one key product.
Boston Scientific Corp BSX News Analytics from Mon, 13 Jan 2025 08:00:00 GMT to Sat, 16 Aug 2025 01:47:12 GMT -
Rating 7
- Innovation -5
- Information 8
- Rumor -1
